08:26 AM EDT, 08/26/2024 (MT Newswires) -- Elevai Labs ( ELAB ) said Monday that its clinical study evaluating the effectiveness of its Elevai Enfinity exosome product on facial appearance demonstrated significant improvements in skin firmness, tone, wrinkles, and smoothness.

The 12-week study, which included 29 participants aged 40 to 70, found the product to be safe and well-tolerated, the company said.

Elevai Labs ( ELAB ) shares jumped nearly 23% in recent Monday premarket activity.

Price: 0.3727, Change: +0.07, Percent Change: +21.40